ChengDa Pharmaceuticals Co. Ltd.301201
▼ NegativeCapitalrelevance
Net profit attributable to parent fell 82.07% year-on-year.
Impact on stocks 1
Others
ChengDa Pharmaceuticals Co. Ltd.Chengda Pharmaceutical's 2026 interim report shows net profit attributable to the parent company of 2.2997 million yuan, down 82.07% from the same period last year. Total operating revenue was 255 million yuan, and net cash inflow from operating activities was 43.2336 million yuan. The asset-liability ratio was 10.69%, gross margin was 30.89%, return on equity was 0.11%, and diluted earnings per share was 0.02 yuan. The number of shareholders was 16,100, and the top ten shareholders held 52.04% of total share capital.
ChengDa Pharmaceuticals Co. Ltd.Net profit attributable to parent fell 82.07% year-on-year.